These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 23239463)
1. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography. Tsuchida T; Morikawa M; Demura Y; Umeda Y; Okazawa H; Kimura H J Magn Reson Imaging; 2013 Jul; 38(1):80-8. PubMed ID: 23239463 [TBL] [Abstract][Full Text] [Related]
2. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899 [TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma. Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944 [TBL] [Abstract][Full Text] [Related]
4. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT. Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444 [TBL] [Abstract][Full Text] [Related]
6. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889 [TBL] [Abstract][Full Text] [Related]
7. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy. Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836 [TBL] [Abstract][Full Text] [Related]
8. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer. Pauls S; Schmidt SA; Juchems MS; Klass O; Luster M; Reske SN; Brambs HJ; Feuerlein S Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700 [TBL] [Abstract][Full Text] [Related]
10. The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Lambrecht M; Deroose C; Roels S; Vandecaveye V; Penninckx F; Sagaert X; van Cutsem E; de Keyzer F; Haustermans K Acta Oncol; 2010 Oct; 49(7):956-63. PubMed ID: 20586658 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163 [TBL] [Abstract][Full Text] [Related]
12. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
13. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer? Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546 [TBL] [Abstract][Full Text] [Related]
14. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results. Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802 [TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Qu X; Huang X; Yan W; Wu L; Dai K Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739 [TBL] [Abstract][Full Text] [Related]
16. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)? Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090 [TBL] [Abstract][Full Text] [Related]
17. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280 [TBL] [Abstract][Full Text] [Related]
18. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules. Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748 [TBL] [Abstract][Full Text] [Related]
19. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes. Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992 [TBL] [Abstract][Full Text] [Related]
20. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better? Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]